QuantalX NeuroScience

QuantalX Neuroscience is a medical device company established by neuroscientists who are committed to revolutionizing the current approach of brain health diagnosis. Together with a dedicated team of developers, scientists, physicians, and business leaders we tackle the clinical, economic, and operational challenges leading to late diagnosis and misdiagnosis of neurodegenerative diseases. Delphi-MD is a first-in-class device providing functional visualization and quantitative analysis for the early detection and differential diagnosis of brain disorders. The Delphi-MD device, powered by a cutting-edge technology, embodies its vision that early diagnosis and access to brain function are crucial in dealing with the significant challenges posed by brain disorders. The company's mission is to transform brain health and disease care, steering in a new era of treatment and support. Delphi-MD was granted FDA Breakthrough designation status twice, for 2 clinical indications. The first is for the detection of early functional and structural brain abnormalities that indicate the early progression of stroke and dementia. And the second for accurately diagnosing NPH (Normal Pressure Hydrocephalus) and predicting the effectiveness of a shunt implant treatment (VPS).

QuantalX NeuroScience has raised $8.6M in total funding across 4 rounds. The company is currently at the Seed stage. Key investors include EMV capital, Katao Venture Partners, Keiretsu Forum Northwest.

QuantalX NeuroScience was founded in 2014 by iftach dolev (Co-founder & CEO), Hilla Fogel (Co-founder & CTO).

QuantalX NeuroScience operates in Health Tech & Life Sciences, Medical Devices, Diagnostics Devices, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Simulation & Imaging. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Life Sciences.

QuantalX NeuroScience is based in HaTahana St 1, Kefar Sava, Israel, Center District.